These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32769882)

  • 21. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
    Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
    United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CT-P13 in the treatment of rheumatoid arthritis.
    Yoo DH
    Expert Rev Clin Immunol; 2017 Jul; 13(7):653-666. PubMed ID: 28571501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness and safety of infliximab biosimilar CT-P13 in treating ulcerative colitis: a real‑life experience in IBD primary centers.
    Tursi A; Allegretta L; Chiri S; Della Valle N; Elisei W; Forti G; Lorenzetti R; Mocci G; Penna A; Pranzo G; Ricciardelli C; Picchio M
    Minerva Gastroenterol Dietol; 2017 Dec; 63(4):313-318. PubMed ID: 28293938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
    Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
    Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy.
    Tursi A; Mocci G; Allegretta L; Aragona G; Bianco MA; Colucci R; Cuomo A; Della Valle N; Ferronato A; Forti G; Gaiani F; Graziani MG; Lorenzetti R; Luzza F; Paese P; Penna A; Pica R; Pranzo G; Rodinò S; Scarcelli A; Zampaletta C; Brozzi L; Cicerone C; Cocco A; De' Angelis G; Donnarumma L; Fiorella S; Iannelli C; Larussa T; Le Grazie M; Luppino I; Meucci C; FaggianI R; Pagnini C; Perazzo P; Rodriguez-Castro KI; Sacco R; Sebkova L; Serio M; De Monti A; Picchio M; Napolitano D; Schiavoni E; Turchini L; Scaldaferri F; Pugliese D; Guidi L; Laterza L; Privitera G; Pizzoferrato M; Lopetuso LR; Armuzzi A; Elisei W; Maconi G; Papa A
    Expert Opin Biol Ther; 2022 Feb; 22(2):313-320. PubMed ID: 34904510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.
    Kim HA; Lee E; Lee SK; Park YB; Lee YN; Kang HJ; Shin K
    BioDrugs; 2020 Feb; 34(1):89-98. PubMed ID: 31734899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
    Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
    Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese Register.
    Marona J; Sepriano A; Ramiro S; Almeida D; Brites L; Couto M; Cunha I; Fernandes BM; Garcia J; Melo AT; Nóvoa T; Oliveira M; Pinto P; Santos MJ; Silva C; Fonseca JE; Araújo FC
    ARP Rheumatol; 2023; 2(2):132-140. PubMed ID: 37421191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.
    Vergara-Dangond C; Sáez Belló M; Climente Martí M; Llopis Salvia P; Alegre-Sancho JJ
    Drugs R D; 2017 Sep; 17(3):481-485. PubMed ID: 28667384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients.
    Pugliese D; Guidi L; Privitera G; Bertani L; Tolusso B; Papparella LG; Maltinti S; Di Mario C; Onali S; Ceccarelli L; Rapaccini GL; Scaldaferri F; Gremese E; Gasbarrini A; Costa F; Armuzzi A
    Expert Opin Biol Ther; 2021 Jan; 21(1):97-104. PubMed ID: 33074723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CT-P13: design, development, and place in therapy.
    Gabbani T; Deiana S; Annese V
    Drug Des Devel Ther; 2017; 11():1653-1661. PubMed ID: 28652703
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial.
    Goll GL; Jørgensen KK; Sexton J; Olsen IC; Bolstad N; Haavardsholm EA; Lundin KEA; Tveit KS; Lorentzen M; Berset IP; Fevang BTS; Kalstad S; Ryggen K; Warren DJ; Klaasen RA; Asak Ø; Baigh S; Blomgren IM; Brenna Ø; Bruun TJ; Dvergsnes K; Frigstad SO; Hansen IM; Hatten ISH; Huppertz-Hauss G; Henriksen M; Hoie SS; Krogh J; Midtgard IP; Mielnik P; Moum B; Noraberg G; Poyan A; Prestegård U; Rashid HU; Strand EK; Skjetne K; Seeberg KA; Torp R; Ystrøm CM; Vold C; Zettel CC; Waksvik K; Gulbrandsen B; Hagfors J; Mørk C; Jahnsen J; Kvien TK
    J Intern Med; 2019 Jun; 285(6):653-669. PubMed ID: 30762274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Høivik ML; Buer LCT; Cvancarova M; Warren DJ; Bolstad N; Moum BA; Medhus AW
    Scand J Gastroenterol; 2018 Jun; 53(6):692-699. PubMed ID: 29852793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.
    Ye BD; Pesegova M; Alexeeva O; Osipenko M; Lahat A; Dorofeyev A; Fishman S; Levchenko O; Cheon JH; Scribano ML; Mateescu RB; Lee KM; Eun CS; Lee SJ; Lee SY; Kim H; Schreiber S; Fowler H; Cheung R; Kim YH
    Lancet; 2019 Apr; 393(10182):1699-1707. PubMed ID: 30929895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial.
    Cohen SB; Radominski SC; Kameda H; Kivitz AJ; Tee M; Cronenberger C; Zhang M; Hackley S; Rehman MI; von Richter O; Alten R
    BioDrugs; 2020 Apr; 34(2):197-207. PubMed ID: 31939063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two-year Outcomes of Infliximab Discontinuation in Patients with Rheumatoid Arthritis: A Retrospective Analysis from a Single Center.
    Takai C; Ito S; Kobayashi D; Nemoto T; Lee H; Abe A; Otani H; Nakazono K; Murasawa A; Ishikawa H
    Intern Med; 2020; 59(16):1963-1970. PubMed ID: 32801270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case report of drug-induced liver injury due to the infliximab biosimilar CT-P13 on switching from original infliximab in a patient with Crohn's disease.
    Kashima S; Sawada K; Moriichi K; Fujiya M
    Ther Adv Drug Saf; 2022; 13():20420986221100118. PubMed ID: 35646305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study.
    Yoo DH; Racewicz A; Brzezicki J; Yatsyshyn R; Arteaga ET; Baranauskaite A; Abud-Mendoza C; Navarra S; Kadinov V; Sariego IG; Hong SS; Lee SY; Park W
    Arthritis Res Ther; 2016 Apr; 18():82. PubMed ID: 27038608
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar.
    Buurman DJ; Blokzijl T; Festen EAM; Pham BT; Faber KN; Brouwer E; Dijkstra G
    PLoS One; 2018; 13(12):e0208922. PubMed ID: 30533022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A descriptive analysis of real-world treatment patterns of innovator (Remicade
    Yazici Y; Xie L; Ogbomo A; Ellis LA; Goyal K; Teeple A; Mutlu EA; Simsek I
    Biologics; 2018; 12():97-106. PubMed ID: 30323555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.